Skip to main content

Table 3 Correlation of EORTC QLQ-C30 and QLQ-H&N 35 (Convergent Validity)

From: Psychometric properties of the Urdu version of the EORTC QLQ-H&N35 (European organization for research and treatment of cancer head and neck module) quality of life tool

 

P

SW

SN

SP

TSE

TSC

LS

T

OM

DM

SS

C

FI

PK

NS

FT

WL

WG

GS

 − 0.43**

 − 0.61**

 − 0.55**

 − 0.45**

 − 0.52**

 − 0.56**

 − 0.39**

 − 0.31**

 − 0.35**

 − 0.19**

 − 0.28**

 − 0.26**

 − 0.59**

0.20**

0.23**

0.37**

0.25**

 − 0.10

PF

 − 0.17**

 − 0.53**

 − 0.36**

 − 0.34**

 − 0.29**

 − 0.39**

 − 0.36**

 − 0.14 *

 − 0.11

 − 0.09

 − 0.13 *

 − 0.15 *

 − 0.47**

0.04

0.24**

0.27**

0.27**

 − 0.14 *

RF

 − 0.38**

 − 0.90**

 − 0.46**

 − 0.42**

 − 0.43**

 − 0.37**

 − 0.34**

 − 0.34**

 − 0.31**

 − 0.19**

 − 0.37**

 − 0.12

 − 0.52**

0.12

0.17**

0.33**

0.27**

 − 0.06

EF

 − 0.42**

 − 0.51**

 − 0.59**

 − 0.40**

 − 0.45**

 − 0.62**

 − 0.40**

 − 0.27**

 − 0.28**

 − 0.18**

 − 0.26**

 − 0.26**

 − 0.60**

0.18**

0.23**

0.24**

0.31**

 − 0.15 *

CF

 − 0.38**

 − 0.42**

 − 0.37**

 − 0.31**

 − 0.29**

 − 0.38**

 − 0.37**

 − 0.24**

 − 0.20**

 − 0.26**

 − 0.19**

 − 0.05

 − 0.40**

0.09

0.21**

0.06

0.17**

 − 0.02

SF

 − 0.36**

 − 0.61**

 − 0.56**

 − 0.55**

 − 0.61**

 − 0.65**

 − 0.44**

 − 0.35**

 − 0.33**

 − 0.27**

 − 0.37**

 − 0.24**

 − 0.63**

0.12

0.24**

0.37**

0.26**

 − 0.04

F

0.44**

0.38**

0.49**

0.34**

0.34**

0.45**

0.21**

0.19**

0.26**

0.13 *

0.26**

0.37**

0.51**

 − 0.23**

 − 0.21**

 − 0.29**

 − 0.28**

0.10

NV

0.43**

0.45**

0.83**

0.35**

0.40**

0.42**

0.32**

0.30**

0.29**

0.25**

0.47**

0.28**

0.45**

 − 0.26**

 − 0.17**

 − 0.30**

 − 0.31**

0.17**

P

0.50**

0.45**

0.50**

0.41**

0.40**

0.45**

0.28**

0.25**

0.26**

0.17**

0.25**

0.26**

0.62**

 − 0.31**

 − 0.23**

 − 0.32**

 − 0.31**

0.10

DY

0.27**

0.41**

0.28**

0.30**

0.29**

0.35**

0.16 *

0.09

0.17**

0.10

0.26**

0.33**

0.30**

 − 0.12

 − 0.08

 − 0.24**

 − 0.22**

0.08

I

0.22**

0.51**

0.40**

0.43**

0.49**

0.43**

0.44**

0.18**

0.21**

0.22**

0.28**

0.09

0.52**

 − 0.14*

 − 0.36**

 − 0.27**

 − 0.29**

0.09

AL

0.31**

0.48**

0.90**

0.35**

0.38**

0.42**

0.29**

0.28**

0.34**

0.22**

0.34**

0.24**

0.46**

 − 0.25**

 − 0.17**

 − 0.34**

 − 0.36**

0.19**

C

0.21**

0.22**

0.34**

0.24**

0.26**

0.32**

0.18**

0.04

0.17**

0.10

0.30**

0.21**

0.29**

 − 0.09

 − 0.20**

 − 0.20**

 − 0.19**

0.11

DI

0.22**

0.26**

0.35**

0.17**

0.19**

0.27**

0.13 *

0.17**

0.15 *

0.20**

0.24**

0.03

0.24**

 − 0.02

 − 0.12

 − 0.15 *

 − 0.14 *

0.11

FD

0.25**

0.37**

0.36**

0.28**

0.34**

0.34**

0.14 *

0.22**

0.38**

0.12

0.25**

0.19**

0.33**

 − 0.18**

 − 0.01

 − 0.42**

 − 0.11

0.05

  1. GS Global scale; PF Physical functioning; RF Role functioning; EF Emotional functioning; CF Cognitive functioning; SF Social functioning; F Fatigue; NV Nausea and vomiting; P Pain; DY Dyspnea; I Insomnia; AL Appetite loss; C Constipation; DI Diarrhea; FD Financial difficulties; P Pain; SW Swallowing; SN Senses; SP Speech; TSE Trouble social eating;TSC Trouble social contact; LS Less sexuality; T Teeth; OM Opening mouth; DM Dry Mouth; SS Sticky saliva; C Coughing; FI Felt ill; PK Pain killers; NS Nutritional supplements; FT Feeding tube; WL Weight loss; WG Weight gain
  2. *significant at p < 0.05;**significant at p < 0.01